Who Generates Higher Gross Profit? Novartis AG or Alnylam Pharmaceuticals, Inc.

A Tale of Two Giants: Novartis AG vs. Alnylam Pharmaceuticals, Inc.

In the world of pharmaceuticals, the battle for supremacy often boils down to financial prowess. Over the past decade, Novartis AG has consistently outperformed Alnylam Pharmaceuticals, Inc. in terms of gross profit. From 2014 to 2023, Novartis AG's gross profit has remained robust, averaging around $34.5 billion annually, while Alnylam's figures have been significantly lower, averaging approximately $399 million.

Despite Alnylam's impressive growth, with a staggering 2,900% increase in gross profit from 2014 to 2023, Novartis's financial muscle remains unmatched. In 2023, Novartis's gross profit was nearly 23 times that of Alnylam. This data highlights the stark contrast between a well-established pharmaceutical giant and a rapidly growing biotech firm. As the industry evolves, it will be intriguing to see if Alnylam can continue its upward trajectory and close the gap with Novartis.